New drug combo for rare leukemia type (ETP-ALL)
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of drugs (venetoclax, azacitidine, chidamide, vindesine, and dexamethasone) in people newly diagnosed with a rare subtype of T-cell acute lymphoblastic leukemia called ETP-ALL or near-ETP-ALL. The goal is to see if this drug cocktail can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 65 years old.
- You must have been newly diagnosed with ETP-ALL, near-ETP-ALL, or T-ALL with certain gene mutations (confirmed by blood cell tests).
- You must not have received any strong chemotherapy for this leukemia yet (some mild treatments are allowed).
- You must be in generally good health with a performance status of 0 to 2 (able to care for yourself and do daily activities without much help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new combination of drugs (venetoclax plus chemotherapy) to standard chemotherapy for people newly diagnosed with a rare type of T-cell leukemia called ETP-ALL. The goal is to see if the new regimen works better.
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a combination of three drugs (venetoclax, olverembatinib, and prednisone) for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combination is safe and effective.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Hear when a new Adult T-cell Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.